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It has been suggested that the bioactive lipid mediator oleoylethanolamide (OEA), a potent agonist of the
peroxisome proliferator-activated receptor-alpha (PPAR-a) possesses anti-depressant-like effects in
several preclinical models. We recently demonstrated that several of OEA's behavioural actions require
the integrity of the brain histaminergic system, and that an intact histaminergic neurotransmission is
speciﬁcally required for selective serotonin re-uptake inhibitors to exert their anti-depressant-like effect.
The purpose of our study was to test if OEA requires the integrity of the histaminergic neurotransmission
to exert its antidepressant-like effects. Immobility time in the tail suspension test was measured to assess
OEA's potential (10mg/kg i.p.) as an antidepressant drug in histidine decarboxylase null (HDC/-) mice
and HDCþ/þ littermates, as well as in PPAR-aþ/þ and PPAR-a/ mice. CREB phosphorylation was eval-
uated using Western blot analysis in hippocampal and cortical homogenates, as pCREB is considered
partially responsible for the efﬁcacy of antidepressants. Serotonin release from ventral hippocampi of
HDCþ/þ and HDC/- mice was measured with in-vivo microdialysis, following OEA administration. OEA
decreased immobility time and increased brain pCREB levels in HDCþ/þ mice, whereas it was ineffective
in HDC/- mice. Comparable results were obtained in PPAR-aþ/þ and PPAR-a/ mice. Microdialysis
revealed a dysregulation of serotonin release induced by OEA in HDC/- mice.
Our observations corroborate our hypothesis that brain histamine and signals transmitted by OEA
interact to elaborate appropriate behaviours and may be the basis for the efﬁcacy of OEA as an
antidepressant-like compound.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
Oleoylethanolamide (OEA) is an endocannabinoid analogue
with multiple, diverse effects on peripheral organs and the brain,
mainly mediated by the activation of peroxisome proliferator-
activated receptor-a (PPAR-a) (Fu et al., 2005; Schwartz et al.,
2008). Recently it was reported that administration of OEA is
effective in a mouse model of depression by using several protocolssani).(Jin et al., 2015). The anti-depressant effect of OEA seems to be
related to the regulation of BDNF in the hippocampus and cortex
(Jin et al., 2015) and to increased levels of serotonin and norepi-
nephrine in brain homogenates (Yua et al., 2015). A selective
agonist of PPAR-a as well produced anti-depressant-like activity by
promoting pCREB/BDNF signaling cascade in the hippocampus and
medial prefrontal cortex (Jiang et al., 2015). Furthermore, recent
evidence reports that OEA exerts neuroprotective effects, prevents
a depressive-like behaviour after ethanol binge administration
(Anton et al., 2017), and participates in the control of reward-
related behaviour (Bilbao et al., 2013).
We recently demonstrated that the activation of the brain his-
taminergic system is necessary for the full expression of some
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driven by the nutritional status in a tissue speciﬁc manner (Fu et al.,
2007) and serves as a hypophagic signal by indirectly activating
central oxytonergic (Gaetani et al., 2010; Romano et al., 2013, 2017)
and histaminergic (Provensi et al., 2014; Umehara et al., 2016)
neural pathways. Also, we found that the activation of histamin-
ergic afferents to the amygdala has a permissive role for the
memory-enhancing effects of OEA (Provensi et al., 2017). Hista-
minergic neurons are conﬁned to the posterior hypothalamus and
innervate virtually the whole brain and partake in the regulation of
homeostatic and cognitive processes by selective activation of
speciﬁc circuits according to the required response (Blandina et al.,
2012; Fujita et al., 2017; Munari et al., 2013). Preclinical studies
conducted in our laboratory demonstrated that an intact hista-
minergic neurotransmission is speciﬁcally required for selective
serotonin re-uptake inhibitors (SSRI) such as citalopram and par-
oxetine to exert their anti-depressant-like effect, as shown by
reduced immobility of mice in the tail suspension test (Munari
et al., 2015). The role of histamine and its receptors in animal
models of depression has been addressed recently (Bahi et al., 2014)
implicating the disinhibition of histamine release in the hippo-
campus as a mechanism of antidepressant-like effects of the his-
tamine H3 receptor antagonists clobenpropit (Femenía et al., 2015).
Indeed, dysfunctions of the hippocampal formation such as hy-
permetabolism (Fitzgerald et al., 2008) or volume reduction
(Posener et al., 2003) have been associated with depressive
symptoms. Furthermore, previous studies demonstrated that
several forms of stress reduce CREB and BDNF levels in the hip-
pocampus and medial prefrontal cortex (mPFC), whereas chronic
antidepressant treatment reverses these molecular changes
(Blendy, 2006; Castren and Rantam€aki, 2010; Razzoli et al., 2011).
Given this premise and the mounting evidence of an interplay
between histamine and OEA, we supposed that the latter required
the integrity of the histaminergic neurotransmission to exert its
antidepressant-like effects. We addressed this question by using
genetically modiﬁed mice that do not produce histamine, (histi-
dine-decarboxylase null mice, HDC/-) and their wild type litter-
mates (HDCþ/þ), or pharmacologically silencing HDC with
intracerebral infusion of the irreversible HDC inhibitor a-ﬂuo-
romethylhistidine (a-FMHis, Garbarg et al., 1980) and subjecting
them to the TST. We also tested the efﬁcacy of OEA in PPAR-a/
mice to understand the participation of this receptor in the
behavioural effects of OEA. We adopted both a repeated and sub-
chronic protocol of OEA administration and, as a neurochemical
readout, we measured CREB phosphorylation in the hippocampi
and frontal cortices of experimental animals. Finally, prompted by
the observation that OEA restores serotonin and noradrenaline
levels in stressed mice (Yua et al., 2015), we measured extracellular
levels of serotonin in the hippocampi of HDC/- and wild type lit-
termates sub-chronically treated with OEA or vehicle.
2. Experimental procedures
2.1. Animals
All animals were housed in macrolon cages in temperature-
controlled rooms (20e24 C), allowed free access to food and wa-
ter, and kept on a 12-h-light/-dark cycle (light started at 7:00 a.m.).
Male.
CD1 mice (25e30 g body weight, Harlan, Italy) were used along
with male inbred HDCþ/þ and HDC/- mice of 11e13 weeks of age
and bred in the Centre for Laboratory Animals, Universita di Firenze
(I) and housed in a dedicated room. The genotype of HDC/- mice
was determined according to the polymerase chain reaction (PCR)
protocol described by Provensi et al. (2014).Male PPAR-aþ/þ and PPAR-a/ (B6.129S4-SvJae-Ppar-
atm1Gonz) mice (25e30 g body weight, Jackson Laboratories),
were bred in the animal facility of the Dipartimento di Farmacia,
Universita di Napoli Federico II, and the colony was established and
maintained by heterozygous crossing. Mice were genotyped as
described on the supplier webpage (http://jaxmice.jax.org), using
the RedExtract kit (SigmaeAldrich, Italy).
All the experiments were performed in strict compliance with
the EEC recommendations for the care and use of laboratory ani-
mals (2010/63/EU) and were approved by the Animal Care Com-
mittee of the Dipartimento di Neuroscienze, Psicologia, Area del
Farmaco e Salute del Bambino, Sezione di Farmacologia e Tossico-
logia, Universita di Firenze (I). Ethical policy of the Universita di
Firenze complies with the Guide for the Care and Use of Laboratory
Animals of the Council Directive of the European Community
(2010/63/EU) and the Italian Decreto Legislativo 26 (13/03/2014).
Every effort was made to minimize animal suffering and to reduce
the number of animals used. Animals were handled for at least 4
days before experiments begun, to let them acclimatise to human
contact.
2.2. Tail suspension test
The Tail suspension test (TST), which is widely used to assess the
antidepressant activity of compounds, was carried out as previ-
ously described (Munari et al., 2015). Brieﬂy, 1 h after the last i.p.
injection of saline or drugs, mice were individually suspended by
the tail to a horizontal ring stand bar (distance from ﬂoor¼ 30 cm)
using adhesive tape (distance from tip of tail¼ 2 cm). Usually, mice
demonstrated several escape-oriented behaviours interspersed
with brief bouts of immobility. A 4-min test sessionwas scored by a
trained observer who was unaware of the treatment and genotype.
Seconds spent immobile were recorded and quantiﬁed by an
experimenter unaware of the treatment. All experimental sessions
were carried out between 9:00 a.m. and 2:00 p..m.. Mice were
randomly assigned to treatment conditions and tested in a coun-
terbalanced order. In the repeated treatments, OEA (5 and 10mg/
kg) or imipramine (10mg/kg) were administered i.p. 24, 5 and 1 h
before the TST, for a total of 3 injections. In sub-chronic treatments,
compounds were injected i.p. once a day for 7 consecutive days and
1 h before exposure to the TSTon the 8th day. Control animals were
injected with vehicle following the same schedule.
2.3. Locomotor activity
Mice were placed in a 55 cm 60 cm plastic arena free to
explore the environment for 5min. Locomotion was recorder with
a camera and the distance travelled was measured on line using the
Smart 2.5 software. The tests were carried out between 9:00 am
and 2:00 p.m. The next day the samemice were exposed to the TST.
2.4. Surgical procedures
To infuse a-FMHis i.c.v., mice were anesthetized with 5% iso-
ﬂurane in humidiﬁed O2 and positioned in a stereotaxic frame
(Stoelting) according to Provensi et al. (2016). A stainless-steel
cannula (7 mm in length, outer diameter 0.5 mm, and inner
diameter 0.25 mm) was implanted in the lateral ventricle and ﬁxed
to the skull using dental cement. The following coordinates were
used according to the mouse brain atlas (Paxinos and Franklin,
1997): AP -0.3; L ± 1; DV -1. After 7 days of recovery, a-FMHis
was infused into the ventricle. A stainless-steel injection micro-
needle was connected through a polyethylene catheter to a 1000-
mL Hamilton precision syringe and then lowered into the lateral
cerebral ventricle (dorsoventral, DV 2.4 mm). a-FMHis was
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the needle was left in place for an additional minute. For micro-
dialysis experiments mice were implanted with one guide cannula
in the ventral hippocampus (vHIPP) according to the following
coordinates from bregma (Paxinos and Franklin, 1997): AP ¼ 3.0,
L ¼ þ3.0, DV ¼ 1.8. A surgical screw served as an anchor, and the
cannula was ﬁxed to the skull with acrylic dental cement.
2.5. Microdialysis
Microdialysis was performed 48 h after surgery to allow formice
recovery, housed one per cage. After removal of the stylet from the
guide cannulae, the microdialysis probes (CMA/7 7/2 Cuprofane;
molecular mass cutoff 6000 Da; CMA Microdialysis) were inserted
and the dialyzing membrane protruded 2mm from the tip of the
cannula. Probeswere perfusedwith KrebseRinger phosphate (KRP)
buffer at a ﬂow rate of 1 mL/min using a microperfusion pump (Mod
CMA/100; Carnegie Medicine, Stockholm, Sweden). The constitu-
ents of the buffer were (in mM) 147 NaCl, 2.4 CaCl2, 4.0 KCl, pH 7.0,
containing 0.5 mM citalopram to improve 5-HT detectability. In our
protocol, OEA was sub-chronically administered (10mg/kg i.p.,
once a day for 8 days) and, 24 h after the last OEA injection, the
microdialysis probe was inserted into the cannula and 30-min di-
alysates were collected after a 2 h stabilization period, in order to
reach a steady state levels of the extracellular basal release of the 5-
HT in the vHIPP of all mice. Spontaneous release was deﬁned as the
average value of the ﬁrst four-30min fractions collected during KRP
solution perfusion. All subsequent fractions were expressed as pg/
ml.
2.6. Determination of 5-HT in the ventral hippocampus
The dialysates were kept at 80 C until analysis. HPLC was
performed as described (Munari et al., 2015). Brieﬂy, 5-HT levels
were assayed by microbore HPLC using a SphereClone 150-
mm  2-mm column (3-mm packing). Detection was accom-
plished with a Unijet cell (BAS) with a 6-mm-diameter glassy car-
bon electrode at þ650 mV vs an Ag/AgCl reference electrode
connected to an electrochemical amperometric detector (INTRO,
Antec Leyden, Netherlands). The chromatographic conditions were:
(1) a mobile phase composed of 85 mM of sodium acetate, 0.34 mM
Ethylenediaminetetraacetic acid (EDTA), 15 mM sodium chloride,
0.81 mM of octanesulphonic acid sodium salt, 6% methanol (vol/
vol), pH ¼ 4.85; (2) a rate ﬂow of 800 mL/min; and (3) a total run-
time of 35 min. A set of standards containing various concentra-
tions of the analyte was prepared in 0.1 M percloric acid solution.
The calibration curves were analysed by linear regression and the
retention times of standards were used to identify peaks; peak
areas were used to extrapolate neurotransmitters levels, calculated
as pmol/30 min.
2.7. Western-blotting analysis
The analysis was performed according to Munari et al. (2015).
Hippocampi and cortices were homogenized in 0.2mL ice-cold
lysis buffer (50mM TrisHCl, pH 7.5, 1M NaCl, 100mM ethylene
glycol tetraacetic acid, 50mM Ethylenediaminetetraacetic acid,
100mM Sodium Pyrophosphate, 40mM Para-
Nitrophenylphosphate, 100mM Na3VO4, 57mM Phenyl-methyl-
sulphonyl ﬂuoride, 2mg/mL leupeptin, 1.7mg/mL aprotinin, 10%
SDS) using a pestle, sonicated brieﬂy, and centrifuged at
12 000 rpm at 4 C for 15min. The supernatant was collected and
protein concentration was determined by Pierce BSA (Thermo
Scientiﬁc). Samples were diluted in a mix of lysis buffer and loading
buffer 2 (1M TrisHCl, pH 6.8, 100mMDL-dithiothreitol (DTT), 10%glycerol, 1% bromophenol blue, and 2% sodium dodecyl sulphate
(SDS)) and boiled for 10min at 95 C. Aliquots containing 40 mg
total proteins were separated on 8% (SDS)-polyacrylamide gel
electrophoresis and transferred to polyvinylidene diﬂuoride
membranes. Blots were blocked in Tris-buffered saline, pH 7.6,
containing 0.1% of Tween 20 (TBS-T) and 5% skimmedmilk (Bio-Rad
Laboratories) for 2 h at room temperature and then incubated
overnight, on different days, with monoclonal antibodies against
pCREB (pCREB-Ser133) (1:1000, catalogue no. 9198) and CREB
(1:1000, catalogue no. 9197, both from Cell Signaling Technology),
that were dissolved in TBS-T with 5% bovine serum albumin.
Membranes were then washed 3 times with TBS-T and incubated
for 120min at room temperature in TBS-T with 1% skimmed milk
containing anti-rabbit peroxidase-conjugated secondary antibody
(1:5000, catalogue no. 7074, Cell Signaling Technology). After
washing in TBS-T 3 times, enhanced chemiluminescence reaction
(Luminata Crescendo, Millipore) was used to visualize the
peroxidase-coated bands. The bands were quantiﬁed by densi-
tometry analysis using an ImageQuant 350 imager and ImageQuant
TL software (Perkin Elmer). pCREB densities were divided by their
respective CREB densities within each sample to obtain pCREB/
CREB ratio values and were averaged for each treatment group.
2.8. Chemicals
a-FMHis (synthesized at Johnson& Johnson Laboratories, a kind
gift of Dr. Nicholas Carruthers) was dissolved in saline. OEA (Tocris
Bioscience, UK) was dissolved in saline/polyethylene glycol/
Tween80 (90/5/5, v/v), whereas imipramine (Sigma) was dissolved
in saline. All other reagents and solvents were of high performance
liquid chromatography (HPLC) grade or the highest grade available
(Sigma).
2.9. Statistical analysis
Statistical signiﬁcance for immobility time and Western blot
analyses was determined using two-way ANOVA followed by
Bonferroni's post hoc test. Microdialysis data were analysed by
two-way ANOVA for repeated measures, with “time” and “treat-
ment” as the two factors, followed by Dunnett's and Bonferroni's
post hoc test formultiple comparisons. 5-HT basal values calculated
as marginal means of the ﬁrst four dialysates samples were sta-
tistically analysed by two-way ANOVA, with “genotype” and
“treatment” as the two factors. Bonferroni's post hoc test was used
as a post hoc test to perform multiple comparisons. The level of
signiﬁcance was set at p< 0.05. Values that were outside the
mean± two deviation standards were discarded.
3. Results
3.1. Effect of OEA on the tail suspension test
We assessed the possible antidepressant-like effect of repeated
or sub-chronic OEA treatment in the TST response of HDC/- mice
and their wild type littermates HDCþ/þ. Imipramine was used a
positive control. Fig.1A shows the effect of different doses of OEA (5
and 10mg/kg) administered 3 times in 24 h. We adopted this
protocol previously (Munari et al., 2015) because three injections of
the antidepressant citalopram during 24 h were shown to be suf-
ﬁcient to produce long-lasting neurochemical changes that are
commonly observed with chronic administration of antidepres-
sants (Mombereau et al., 2010). OEA decreased immobility time in
HDCþ/þ mice at both doses used, whereas it was ineffective in
HDC/-. Data were subjected to a 2-way ANOVA to examine the
effect of genotype and repeated OEA treatment on immobility time.
Fig. 1. Behavioural and neurochemical effects of OEA in mice genetically deprived of
histamine. Schematic representations of the protocols used to evaluate vehicle, OEA or
imipramine effects on the tail suspension test (TST) are shown at the top of panels A
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notype x treatment) 3,69¼ 5.026, p< 0.001); F(treatment) 3,69¼12.85,
p< 0.0001; (F(genotype)1,69¼ 4.446 p< 0.05). Bonferroni's post hoc
test showed that both doses of OEA signiﬁcantly decreased the
immobility time of HDCþ/þ mice exposed to the TST (5mg/kg,
p< 0.01; 10mg/kg, p< 0.001), whereas no signiﬁcant effects were
observed in HDC/ mice. Imipramine decreased the immobility
time of both genotypes (HDCþ/þ andHDC/, p< 0.001; Fig.1A).We
also investigated the effect of OEA on the TST in CD1 mice that
received i.c.v. injections of a-FMHis, an irreversible HDC inhibitor,
to verify if the absence of brain histamine is indeed responsible for
the lack of OEA's effect in HDC/mice (Fig. 2). In analogy with
HDC/mice, OEA did not modify the immobility time of a-FMHis-
treated mice, whereas imipramine remained effective regardless of
the presence of brain histamine (F(icv x treatment) 3,79¼ 4.707,
p< 0.01); F(treatment) 3,79¼ 43.62, p< 0.0001; F(icv) 1,79¼ 5.007,
p< 0.05). Signiﬁcant differences for OEA treatments by Bonferroni's
post hoc test were p< 0.001.
OEA sub-chronic treatment produced similar behavioural re-
sults. We adopted the sub-chronic administration protocol to
exclude that mice developed tolerance to the behavioural effect of
OEA. Either OEA or imipramine were administered i.p. for 8
consecutive days, and the last injection 1 h before the test (Fig. 1B).
A 2-way ANOVA showed signiﬁcant differences between groups
(F(genotype x treatment) 3,57¼ 3.362, p< 0.05); F(treatment) 3,57¼ 7.418,
p< 0.001; (F(genotype)1,57¼10.34 p< 0.01). Bonferroni's post hoc
analysis revealed that OEA treatment at all doses tested signiﬁ-
cantly reduced the immobility time of HDCþ/þ mice (5mg/kg and
10mg/kg OEA, p< 0.01), whereas no effect on immobility time was
observed in HDC/mice. Imipramine reduced the immobility time
of both genotypes (HDCþ/þ, p< 0.01; in HDC/, p< 0.05).3.2. Effect of OEA on CREB phosphorylation of HDCþ/þ and HDC/-
mice hippocampus and prefrontal cortex
Administration of antidepressants increases CREB phosphory-
lation in the hippocampus, supporting the hypothesis that pCREB is
at least in part responsible for the efﬁcacy of these medications
(Blendy, 2006). Using the sub-chronic regimen, we compared the
effect of OEA (10mg/kg) imipramine (10mg/kg) and vehicle-
treated HDCþ/þ and HDC/- mice. Two-way ANOVA showed an
overall signiﬁcant difference between groups (F(genotype x treatment)
2,21¼4.14, p< 0.05; F(treatment) 2,21¼14.05, p¼ 0.0001; F(genotype)
1,21¼11.56, p< 0.05). Bonferroni's post hoc test found signiﬁcant
differences between groups (Fig. 1CeD). OEA signiﬁcantly
increased pCREB in the hippocampus of HDCþ/þ mice compared
with vehicle treated animals (Bonferroni's post hoc test p< 0.01;
Fig. 1C). However, OEA treatment was ineffective in HDC/ mice
(Fig. 1C), as pCREB levels were not different from those of vehicle-
treated mice. Similar to the effect in the hippocampus, OEA
increased pCREB levels in the frontal cortex of HDCþ/þ mice
(p< 0.05; Fig. 1D), but not in the cortex of HDC/- mice (2-way
ANOVA, F (genotype x treatment) 2,24¼ 3.78, p< 0.05; F(treatment)
2,24¼ 6.78, p< 0.01; F(genotype)1,24¼ 3.57, p¼ 0.07). Imipramine
administered at 10mg/kg for 8 days increased pCREB in the(repeated) and B (subchronic). Vehicle (VEH), OEA or imipramine were delivered i.p. 1
hr before the TST. In both protocols, OEA reduced immobility time of HDCþ/þ but not of
HDC/- mice. The tricyclic antidepressant imipramine decreased immobility time of
both genotypes. Shown are means ± SEM of 8e12 mice for each group; *P < 0.05,
**P < 0.01 and ***P < 0.001 vs VEH within each genotype. Subchronic administrations
of OEA increased pCREB/CREB ratio in the hippocampus (C) and cortex (D) of HDCþ/þ
but not of HDC/- mice, as shown by Western-blot analysis. Imipramine was effective
in both genotypes. Shown are means ± SEM of 8e10 mice for each group; *P < 0.05,
**P < 0.01 vs VEH within each genotype.
Fig. 2. Behavioural effects of OEA in mice acutely deprived of brain histamine. Sche-
matic representation of the protocol used to evaluate saline, OEA or imipramine effects
on the tail suspension test (TST) is shown at the top of the ﬁgure. CD-1 mice were
injected i.c.v. with alpha-ﬂuoromethylhistidine (a-FMHis) 24 h before the TST. Vehicle
(VEH), OEA or imipramine were i.p. 1 hr before testing. Represented are means ± SEM
of 8e10 mice., ***P < 0.001 vs VEH.
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(p< 0.05).3.3. PPAR-a is necessary for the effects of OEA on TST and CREB
phosphorylation
To explore if PPAR-a is required for the antidepressant-like ef-
fect of OEA, PPAR-a þ/þ and PPAR-a/ mice were tested in the TST
after repeated or sub-chronic OEA (10mg/kg) treatments as shown
in Fig. 3AeB. A 2-way ANOVAwas conducted to examine the effect
of genotype and repeated (3  in 24 h) treatment on immobility
time that revealed an overall signiﬁcant difference between groups
(F(genotype x treatment) 1,29¼ 5.925, p< 0.05); F(treatment) 1,29¼11.80,
p< 0.01; (F(genotype)1,29¼ 0.788 p¼ 0.38). Bonferroni post-hoc test
showed that OEA repeated treatment signiﬁcantly decreased the
immobility time of PPAR-aþ/þmice (p< 0.001), but not of PPAR-a/
 mice. Qualitatively similar results were obtained with a sub-
chronic treatment (1 8 days; Fig. 3B). There was a statistically
signiﬁcant interaction between the effect of genotype and treat-
ment (F(genotype x treatment) 1,27¼ 9.147; p¼ 0.0054), but there were
no signiﬁcant effects of single variables (F(treatment) 1, 27¼ 2.943,
p¼ 0.09; F(genotype) 1,27¼1.206; p¼ 0.28). Bonferroni's post hoc
analysis showed that OEA was effective at reducing immobility
time only in PPAR-aþ/þ (p< 0.05). Using the sub-chronic regimen,
we compared the effect of OEA (10mg/kg) and vehicle treatment on
CREB phosphorylation in PPAR-aþ/þ and PPAR-a/ mice. In the
hippocampus, 2-way ANOVA showed an overall signiﬁcant effect
on interaction and treatment (F(genotype x treatment) 1,30¼10.9,
p< 0.05; F(treatment) 1,30¼ 23.39, p¼ 0.001), but not on genotype
(F(genotype) 1,30¼1.33, p¼ 0.4). OEA increased signiﬁcantly pCREB in
the hippocampus of PPAR-aþ/þmice compared with vehicle treated
animals (Bonferroni's post hoc test p< 0.01; Fig. 3C), whereas no
effect was observed in PPAR-a/ mice. In the cortices two-way
ANOVA showed an overall signiﬁcant effect on interaction and
treatment (F(genotype x treatment) 1,29¼ 95.991 p< 0.05; F(treatment)
1,29¼ 4.631, p< 0.01), but not on genotype (F(genotype) 1,29¼ 2.047
p¼ 0.16). OEA increased pCREB in cortical homogenates of PPAR-
aþ/þ mice as revealed by Bonferroni's post hoc test (p< 0.01).3.4. General motility
To exclude possible effects of the various treatments and ge-
notypes on spontaneous locomotor activity that may have affected
the immobility time in the TST, mice were exposed to the open ﬁeld
and motor activity recorded for 5min. No differences were
observed between experimental groups in the repeated treatment
nor in the sub-chronic treatment (Fig. S1).
3.5. Functional response of the hippocampal 5-HT system of HDCþ/
þ and HDC/- mice
To address the impact of sub-chronic OEA treatment on the
serotonergic transmission we performed a microdialysis experi-
ment in the vHIPP of both HDCþ/þ and HDC/- mice. In this
experiment both the basal 5-HT tone and the impulse-driven 5-HT
release were estimated by perfusing the probes ﬁrst with KRP
buffer (basal condition), and then with Kþ-enriched KRP buffer
(containing KCl 100mM) for 30min (stimulated condition; Fig. 4A
and B). The overall basal concentrations of extracellular 5-HT
(calculated as the marginal means of the ﬁrst four dialysates)
measured in the presence of 0.5 mM citalopram in the perfusion
medium are reported in Fig. 4 C. Two-way ANOVA analysis of basal
5-HT levels in the vHIPP of HDCþ/þ and HDC/- mice revealed a
signiﬁcant main effect of genotype (F1,17¼6.195 p< 0.05), whereas
no signiﬁcant main effect of treatment (F1,17¼ 0.245, p¼ 0.629) and
interaction (F1,17¼ 0.493, p¼ 0.495) was observed. Post hoc test
showed that sub-chronic OEA treatment signiﬁcantly decreased
(26%) the 5-HT basal output of HDC/- mice compared to OEA-
treated HDCþ/þ mice (p< 0.05; Fig. 4C). Kþ-stimulation signiﬁ-
cantly increased the extracellular 5-HT release in the vHIPP of
HDCþ/þ mice treated with either vehicle or OEA (two-way ANOVA
for repeated measures: Ftime (1,9)¼ 7.012 p< 0.05; Ftreatment
(1,9)¼ 3.118 p¼ 0.121; Ftime x treatment (1,9)¼ 1.104 p¼ 0.349). In
particular, 30min after high Kþ retrodialysis administration, 5-HT
reached 654 and 840 pg/ml in vehicle- (87% of basal values,
p< 0,05) and OEA-treated (136% of basal values, p< 0,05) HDCþ/þ
mice, respectively (Fig. 4A).
Conversely, statistical analysis of 5-HT output under stimulation
condition in the HDC/- mice revealed a signiﬁcant main effect of
time (F1,8¼ 7.695 p< 0.05) and treatment (F1,8¼ 7.870 p< 0.05),
but not time-by-treatment interaction (F1,8¼ 2.039 p¼ 0.184). Post
hoc analysis (Dunnett's test) showed a greater response to Kþ
stimulation in HDC/- mice treated with OEA compared to the
vehicle-treated HDC/- mice (Fig. 4B). In fact, in the vHIPP of OEA-
treated HDC/- mice the 5-HT levels reached 1122 pg/ml (327% of
basal values, p< 0,05) 30min after the beginning of Kþ-stimulation,
whereas, at the same time-point, extracellular 5-HT levels peaked
at 574 pg/ml (93% of basal values, p< 0,05) in vehicle-treated
HDC/- mice. Moreover, Bonferroni's post hoc test showed a sta-
tistically signiﬁcant difference between vehicle- and OEA-treated
HDC/- mice 30min after high Kþ retrodialysis administration
(p< 0.05).
4. Discussion
The ﬁrst intuition that OEA may have antidepressant-like
properties dates back to the work by the group of Piomelli
(Bortolato et al., 2007) who showed that a fatty acid amide hy-
drolase (FAAH) inhibitor increased the cerebral levels of the
endocannabinoids anandamide, OEA and palmitoylethanolamide
and corrected the alterations associated with chronic mild stress, a
validated rat model of depression. The ﬁnding that OEA activates
the central oxytonergic system (Gaetani et al., 2010) and the well-
known role of this system in major depressive disorders (Romano
Fig. 3. Behavioural and neurochemical effects of OEA in mice genetically deprived of
PPAR-a. Schematic representations of the protocols used to evaluate vehicle or OEA
effects on the tail suspension test (TST) are shown at the top of panels A (repeated) and
B (subchronic). Vehicle (VEH) and OEA were delivered i.p. 1 hr before the TST. In both
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More recently, OEA was found to decrease the immobility time
of mice exposed to the TST (Jiang et al., 2015), a test that evaluates
stress-coping behaviour of mice, rather than depression-associated
behaviour, and to normalize several activities and neurochemical
parameters affected by chronic mild stress (Jin et al., 2015). In the
past years, we provided evidence of a neurobiological pathway
between OEA and brain histamine (Provensi et al., 2014, 2017) and
here, we examined if OEA requires the integrity of the brain his-
tamine system to exert its antidepressant-like effect as well. We
used the TST, as all antidepressants effectively reduce immobility in
this test (Lucki et al., 2001), without attempting to reproduce a
model of chronic stress or depression. We found that OEA
decreased the immobility time of HDCþ/þ mice, but did not
decrease that of HDC/- mice, nor it affected the immobility time of
mice with pharmacological depletion of brain histamine. Accord-
ingly, OEA augmented pCREB in the hippocampus and cortex of
HDCþ/þ mice, but not in the brain of HDC/- mice. Creb phosphor-
ylation is one of the molecular mechanisms associated to the efﬁ-
cacy of SSRI treatment (Carlezon et al., 2005) and is required for TST
response to citalopram (Gur et al., 2007).The tricyclic antidepres-
sant imipramine, however, was effective in both parameters irre-
spective of brain histamine availability. In this respect, OEA
behaved exactly like SSRIs, as we earlier found that an intact his-
taminergic neurotransmission is required speciﬁcally for cit-
alopram and paroxetine (but not the TCA imipramine, nor the
selective NA reuptake inhibitor reboxetine) to reduce the immo-
bility time in the TST and to modulate pCREB expression (Munari
et al., 2015).
The ability to enhance serotonergic transmission is a feature
common to SSRIs, therefore to assess if OEA also shares this char-
acteristic we measured 5-HT outﬂow in the vHIPP, a region pri-
marily involved in regulating stress, emotion, and anxiety
(Bannerman et al., 2003), of both HDCþ/þ and HDC/- mice. We
found that sub-chronic OEA administrations did not enhance 5-HT
outﬂow of HDCþ/þ compared to vehicle treatedmice, as assessed by
in vivo microdialysis. Surprisingly, though, OEA signiﬁcantly
decreased 5-HT basal outﬂow in the vHIPP of HDC/- mice
compared to OEA-treated HDCþ/þ mice. The basal activity of the
serotonergic transmission in the hippocampus of HDC/- mice
treatedwith vehicle did not appeared different form that of HDCþ/þ
mice, which is in agreement with our previous observation that
HDC/- mice do not show desensitization of 5-HT1A receptors, nor
insensitivity to SSRI administration (Munari et al., 2015). However,
OEA-treated HDC/- mice appeared 'supersensitive' to the acute Kþ
challenge, with respect to HDCþ/þ mice. We cannot offer at this
point an explanation for this response, nor we can assert that the
dysregulation of 5-HT release induced by OEA in HDC/- mice
contributes to the inefﬁcacy in the TST. Our experiments though, do
not agree with the reported 5-HT increase in whole mice brain
homogenates (Yua et al., 2015). However, we propose a neuronal
circuitry responsible for the results reported here, based on our
previous and actual observations.We previously demonstrated that
OEA increases histamine release and neuronal activation in a brain
region- and behavioural status-dependent manner (Provensi et al.,
2014, 2017). OEA, though, does not increase c-fos expression in
selected brain regions of HDC/- mice except for the nucleus of theprotocols, OEA reduced the immobility time of PPAR-aþ/þ but not of PPAR-a/ mice.
Shown are means ± SEM of 7e10 mice for each group; *P < 0.05, ***P < 0.001 vs VEH
within each genotype (Bonferroni's post hoc test). Subchronic administrations of OEA
increased pCREB/CREB ratio in the hippocampus (C) and cortex (D) of PPAR-aþ/þ but
not of PPAR-a/mice, as shown by Western-blot analysis. Shown are means ± SEM of
7e8 mice for each group; *P < 0.05, **P < 0.01 vs VEH within each genotype (Bon-
ferroni's post hoc test).
Fig. 4. Effects of vehicle (veh) or OEA administration on the basal and Kþ-stimulated
(horizontal black line) 5-HT extracellular levels in the vHippo of HDCþ/þ (A) and
HDC/- (B) freely moving mice. Data are expressed as mean ± S.E.M. *P < 0.05;
**P < 0.01 versus basal mean within the same group (Dunnett's multiple comparison
test). P < 0.05 versus HDC/- veh mice (Bonferroni's test for between groups com-
parisons). Basal 5-HT extracellular levels (C, calculated as marginal means of the ﬁrst
four dialysate samples) in the vHippo of HDCþ/þ and HDC/- mice treated with either
vehicle or OEA during microdialysis experiment. Data are expressed as mean ± SEM.
*P < 0.05 versus HDCþ/þ in the same treatment group (Tukey's test; N¼ 5e4).
A. Costa et al. / Neuropharmacology 135 (2018) 234e241240solitary tract (NST), the primary brainstem area activated by vagal
afferents relaying OEA signaling from the periphery (Umehara
et al., 2016). We therefore believe that OEA-induced NST activa-
tion precedes the stimulation of the histaminergic system, strongly
suggesting that in HDC/- mice the NST activated by OEA sends
signals to the TMN via presumably noradrenergic ﬁbers (Provensi
et al., 2014), but histaminergic neurons are not available to relay
information further along histaminergic pathways. One of these
pathways leads to the activation of H1 and H2 receptors in the
hippocampus, a region responsible of the antidepressant-like re-
sponses induced by increased histamine release (Femenía et al.,
2015). Here we demonstrated that in the hippocampus of HDCþ/
þmice OEA increased pCREB, a feature common to other PPAR-a
agonists such as fenoﬁbrate with antidepressant like effects (Jiang
et al., 2017), but not in HDC/- mice, although the CREB intracel-
lular machinery is not impaired in these animals (Munari et al.,
2015). In this respect, OEA and SSRI appear to interact with the
histaminergic system in a different manner; as we previously
proposed (Munari et al., 2015), the inefﬁcacy of SSRIs in the TST and
CREB phosphorylation of HDC/- mice could be attributed to the
disruption of a raphe-TMN loop, whereas OEA appears to bypass
the serotonergic system, as it does not signiﬁcantly affect 5-HT
release from the hippocampus of normal mice.
It has been proposed that OEA may act via other receptors, such
as the vanilloid receptor TRPV1 (Wang et al., 2005), or the GPR119
receptor (Overton et al., 2006) to control food intake, and via as yet
unknown receptors to reduce pain (Suardíaz et al., 2007). Our re-
sults demonstrate that activation of PPAR-a mediates the behav-
ioural and neurochemical actions of OEA, as OEA did not reduce the
immobility, nor increased pCREB in PPAR-a/ mice, suggesting
that these nuclear receptors play an important role in the proper-
ties of OEA here reported.
Neuronal histamine has been described in several species, from
Drosophila (reviewed in N€assel, 1999) to humans (reviewed in
Panula and Nuutinen 2013); the behavioural effects of OEA as well,
which is normally secreted by enterocytes after a fatty meal, have
been described in lesser vertebrate species (Astarita et al., 2006)
and in humans (Schaefer et al., 2014). The observations that we
present here corroborate our hypothesis that these two phyloge-
netically ancient systems interact and that the central histaminer-
gic system, at least in rodents, receives signals coming from
peripheral organs and transmitted by OEA to elaborate the appro-
priate behaviour and homeostatic responses.
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